The success of hematopoietic stem-cell transplantation (HSCT) with reduced-intensity conditioning (RIC) is limited by a high rate of disease relapse. Early risk assessment could potentially improve outcomes by identifying appropriate patients for pre-emptive strategies that may ameliorate this high risk. Using a series of landmark analyses, we investigated the predictive value of early (day-30) donor chimerism measurements on disease relapse, graft-versus-host disease and survival in a cohort of 121 patients who were allografted with a uniform RIC regimen. Chimerism levels were analyzed as continuous variables. In multivariate analysis, day-30 whole blood chimerism levels were significantly associated with relapse (HR=0.90, p<0.001), relapsefree survival (HR=0.89, p<0.001) and overall survival (HR=0.94, p=0.01). Day-30 T-cell chimerism levels were also significantly associated with relapse (HR=0.97, p=0.002), relapse-free survival (HR=0.97, p<0.001) and overall survival (HR=0.99, p=0.05). Multivariate models that included T-cell chimerism provided a better prediction for these outcomes compared to whole blood chimerism. Day-30 chimerism levels were not associated with acute or chronic graft-versushost disease. We found that high donor chimerism levels were significantly associated with a low lymphocyte count in the recipient prior to transplant, highlighting the impact of pre-transplant Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. lymphopenia on the kinetics of engraftment after RIC HSCT. In summary, low donor chimerism levels are associated with relapse and mortality and can potentially be used as an early predictive and prognostic marker. These findings can be used to design novel approaches to prevent relapse and to improve survival after RIC HSCT.
INTRODUCTION
Reduced intensity conditioning (RIC) regimens are associated with decreased treatmentrelated mortality and make allogeneic hematopoietic stem-cell transplantation (HSCT) feasible in older patients and those with comorbidities. The primary barrier to the success of RIC HSCT is disease relapse [1] . The risk of relapse after RIC is 25-60% [2] [3] [4] [5] [6] [7] , and the median time to disease relapse is 3-7 months [8-11], implying that identification of patients at high-risk for relapse should be done very early, optimally within the first few weeks after transplant. The ability to detect relapse early in the post-transplant period is fundamental to the design of interventions that can potentially prevent disease recurrence and improve survival such as maintenance regimens or pre-emptive donor lymphocyte infusions (DLI).
The level of donor-recipient chimerism is an established method to document donor engraftment [12] , and can be conducted in whole blood, bone marrow and in cellular subsets such as T-cells, myeloid cells and CD34+ cells [13, 14] . The kinetics of donor chimerism after myeloablative transplants have been characterized, but associations between attainment of complete donor chimerism and disease relapse or survival have not been consistently demonstrated [15] [16] [17] [18] .
In contrast to myeloablative transplants, RIC HSCT frequently results in varying degrees of mixed chimerism that may persist for months [19, 20] , but the underlying biological features that determine this heterogeneity among patients are not well characterized. In addition, previous studies of RIC HSCT have shown conflicting results regarding the correlation between early chimerism levels and disease relapse [19] [20] [21] [22] . As a result, there is uncertainty in how to interpret chimerism measurements in this setting, therefore limiting their clinical utility.
Our goal was to examine the utility of early chimerism measurement for prediction of disease relapse, graft-versus-host disease (GvHD) and survival. We therefore used a landmark analysis to investigate the predictive power of day-30 whole blood (WB) and Tcell chimerism levels for subsequent outcomes of patients undergoing RIC HSCT with a uniform and commonly used conditioning regimen.
METHODS

Patients and treatment
We reviewed data on adult recipients of a first allogeneic peripheral blood HSCT who were allografted with a uniform RIC regimen (fludarabine + busulfan) for a malignant hematological disorder between August 2006 and April 2013 at the University of Pennsylvania. We excluded patients who were transplanted for primary myelofibrosis where it is difficult to accurately define relapse and patients who did not have available results of day-30 chimerism levels. Since graft rejection was rare in this cohort (n=3), we excluded these patients. Our study population included 121 patients. To account for the heterogeneity of the cohort in disease type and disease burden, we reviewed relevant disease characteristics (i.e., cytogenetics in AML and MDS, disease subtype in MDS, disease stage and status in all diseases) and calculated the Disease Risk Index (DRI), a stratification system that predicts overall survival based on disease parameters. We used the 3-group version of the DRI that was recently validated using a large dataset from the Center for International Blood and Marrow Transplant Research (CIBMTR) [23] . Additional variables that were collected were the Karnofsky performance status and the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) [24] . The Institutional Review Board of the University of Pennsylvania approved the study. All participants provided written informed consent for data collection at the time of their transplant.
All participants received a uniform conditioning regimen of fludarabine i.v. 120 mg/m 2 and busulfan i.v. 6.4 mg/kg, followed by the infusion of granulocyte colony-stimulating factormobilized peripheral blood stem cells from either a related or an unrelated donor. T-cell depletion was not used. Participants received standard GvHD prophylaxis with oral tacrolimus 0.06 mg/kg/d or cyclosporine 5 mg/kg/d in 2 divided doses starting on day −3 and intravenous methotrexate 15 mg/m 2 on day 1 and 10 mg/m 2 on days 3, 6 and 11. Tacrolimus and cyclosporine doses were adjusted to attain trough levels between 5-15 ng/ml and 200-400 ng/ml respectively. Some patients (n=29) received maraviroc, a CCR5 antagonist, as part of a clinical trial in GvHD prophylaxis at doses of 150 mg or 300 mg twice daily between day −2 and day +30 [25] . All participants received standard antimicrobial prophylaxis. Patients did not receive prophylactic DLI. Donor-recipient chimerism levels were measured in the peripheral blood on day 30 using short tandem repeat analysis [26, 27] . Chimerism levels were measured in WB samples and in the T-cell subset after immunomagnetic positive selection of CD3+ cells. (StemCell Technologies, Vancouver, Canada). The graft composition, including the nucleated cell dose and the CD34+, CD3+, CD4+ and CD8+ cell doses were determined using standard procedures [28] . Absolute lymphocyte counts (ALC) were measured on routine complete blood counts on day-6 prior to starting the conditioning regimen, and again on day 0, prior to the stem-cell infusion.
Clinical outcomes
The clinical outcomes of interest were time to disease relapse, grade II-IV acute GvHD, moderate-severe chronic GvHD, relapse-free survival and overall survival. Disease relapse was defined as morphologic, cytogenetic or radiologic evidence of disease demonstrating pre-transplant characteristics. Bone marrow biopsies and appropriate imaging studies were routinely performed at day 100 or earlier in patients with signs indicating early relapse. The consensus conference criteria and NIH criteria were used for acute and chronic GvHD grading respectively [29, 30] .
Statistical analysis
Descriptive statistics were employed to characterize distributions of variables. Linear correlations between WB and T-cell donor chimerism at day 30 and other continuous variables were assessed by Pearson's correlation coefficient and differences between groups defined by categorical variables were assessed by either Wilcoxon rank sum or KruskalWallis tests. No adjustment for multiple testing was performed in the analysis of predictors of chimerism levels. A landmark approach was used for time-to-event outcomes by measuring the time from chimerism measurement (approximately day 30) to the event, which allowed us to evaluate day-30 WB and T-cell donor chimerism as predictors. Time to relapse was defined as the time from day-30 chimerism measurement to first documented relapse or last patient contact without relapse. Other outcomes were similarly defined. Patients were censored at the time of a second transplant in all analyses and at the time of DLI for GvHD analyses. Competing risks regression analyses were conducted to identify predictors of time to relapse and time to GvHD outcomes, allowing for death without the event as a competing risk. Cox regression was used to identify predictors of survival and relapse-free survival. Univariate and multivariate analyses were performed to identify significant independent predictors and the primary variables of interest, day-30 WB and Tcell chimerism, were entered into all models separately. The GvHD prophylaxis regimen was entered as a fixed covariate in the models for adjustment only since patients were not randomized to these treatments. Additional variables considered for model building exhibited univariate significance of p≤0.10 and a step-wise elimination method was then used. Statistical significance of predictors in the models was assessed by the Wald test. The Akaike Information Criterion (AIC) was used to assess the relative goodness of fit of the models built for WB and T-cell chimerism. Analyses were conducted in STATA v13.1 (STATA Corp, College Station, TX) and R using the cmprsk package (The R Project for Statistical Computing, http://www.rproject.org).
RESULTS
Patient and transplant characteristics are summarized in Table 1 . The median follow up was 22.5 months (range 1.4-57.9 months). The median day-30 WB chimerism level was 96% (range 77-100%). T-cell chimerism levels were available in 103 of 121 patients; the median day-30 T-cell chimerism was 65% (range 18-100%).
Predictors of day-30 chimerism levels
Our goal was to assess the associations between day-30 chimerism levels and RIC HSCT outcomes. We first examined whether day-30 chimerism levels were associated with various patient, disease and transplant characteristics ( Table 2 ).
The primary variable that was associated with day-30 chimerism levels was the recipient's ALC prior to transplant. Low ALC, both pre-conditioning (day minus 6) and on day-0, was strongly associated with higher levels of WB and T-cell chimerism levels (Figure 1 , p≤0.0001 for all associations). The DRI showed a significant association with day-30 WB chimerism and a trend (p=0.07) with day-30 T-cell chimerism with higher disease risk correlating with lower chimerism levels. In addition, the total nucleated cell dose demonstrated a positive association with WB and T-cell chimerism, female recipients had slightly higher WB chimerism and HLA-mismatching resulted in higher T-cell chimerism levels. The use of tacrolimus vs. cyclosporine was associated with lower T-cell chimerism, and maraviroc did not seem to affect chimerism levels.
We wanted to check whether the association between pre-transplant ALC and day-30 chimerism was driven primarily by patients with lymphoid malignancies who are more likely to receive lymphodepleting therapies prior to transplant. Surprisingly, we found that recipients' ALC was associated with day-30 chimerism levels regardless of disease type (Table 3 ). Both pre-conditioning and day-0 ALC were highly correlated with WB and T-cell chimerism in both lymphoid and myeloid diseases (p<0.005). The only association that was strong but did not reach statistical significance was between pre-conditioning ALC and WB chimerism in myeloid disease (p=0.08). These results demonstrate that pre-transplant lymphopenia may support early engraftment regardless of disease.
Relapse
Disease relapse, a major cause of mortality following RIC HSCT, was our primary focus. The cumulative incidence of relapse was 37.7% (95% CI [29.7-47.1]) at day 180 and 46.3% (95% CI [37.7-55.9]) at 1 year. The 1-year incidence of relapse in AML, MDS and NHL, the most common diseases in our cohort, was 39.4%, 46.3% and 56.1% respectively (p>0.05 for all comparisons).
To assess the predictive power of day-30 chimerism on relapse, we used a landmark analysis approach starting on the day of chimerism measurement (approximately day 30). Three patients who relapsed prior to the landmark date were excluded. We first assessed the effect of each covariate independently of others (Table 4 ) and then built a multivariate model for prediction of time to relapse (Table 5) . Importantly, chimerism levels were analyzed as continuous variables and therefore the hazard ratios reflect the increased or decreased risk for the outcome for each 1% difference in chimerism levels.
In univariate analysis, the day-30 WB chimerism level was significantly associated with a reduction in relapse (HR=0.90, 95% CI [0.86-0.94]; p<0.001). This strong association reflects a 10% decrease in the relapse risk for every 1% increase in WB chimerism levels. Day-30 T-cell chimerism levels also demonstrated an inverse association with relapse (HR=0.98, 95% CI [0.97-1.00], p=0.02). Other variables that were associated with relapse and met our threshold for modeling included donor or recipient sex and the GvHD prophylaxis regimen (cyclosporine vs. tacrolimus). Because the GvHD prophylaxis regimen was not selected by randomization, it was treated as a confounder and used for adjustment only. In addition, low CD8 cell doses and a high graft CD4/CD8 ratio correlated with a higher risk for relapse.
To further characterize the association between day-30 chimerism and disease relapse and identify a chimerism threshold that optimally predicts relapse, we examined all possible cutoffs. For WB chimerism, there was a strong association at any relevant cutoff, precluding a choice of an optimal cutoff for prediction of relapse. For example, cutoffs of 90%, 93% and 96% resulted in hazard ratios of 0.26, 0.25 and 0.44, respectively (all three cutoffs with p<0.01). As a representative example, cumulative incidence plots that compare disease relapse in patients grouped according to the median WB chimerism level (96%) are displayed in Figure 2A . We plotted the p-values for this association against all cutoff levels to demonstrate that this association was continuous, highly significant and consistent across multiple cutoff levels ( Figure 2B ).
T-cell chimerism levels also predicted disease relapse at multiple cutoffs. For example, a comparison of relapse rates in patients with day-30 T-cell chimerism above and below the median (65%) showed a hazard ratio of 0.56 (p=0.05; Figure 2C ). We assessed different cutoff levels for T-cell chimerism and found that the distribution of p-values was asymmetric. Cutoffs that were at the median level or lower provided a better prediction than higher cutoffs ( Figure 2D ). Still, we could not identify a single optimal cutoff.
We then wanted to assess whether day-30 chimerism levels were prognostic as opposed to diagnostic because it is possible that patients with low chimerism levels had already relapsed on day 30. To ascertain that the associations that we found were not driven by patients with very early relapse, we repeated our analysis after excluding 6 patients who experienced relapse between day 30 -60. We found that the ability to predict relapse was unchanged after excluding these early relapse patients (WB: HR=0.90, p<0.001; T-cell: HR=0.98, p=0.02). This confirms that there was a window of opportunity for intervention in the majority of patients with low chimerism levels.
Finally, both WB and T-cell chimerism levels were strong predictors of relapse in multivariate models that were constructed separately for each predictor (Table 5 ). High DRI, male donors and grafts with a high CD4/CD8 cell dose ratio remained significant predictors for a high relapse rate. No differential effect (i.e. statistical interaction) was noted between subsets of patients with myeloid and lymphoid disease (p=0.66), acute leukemia and other diseases (p=0.58) or unrelated and sibling donors (p=0.71).
Relapse-free survival and overall survival
Due to their highly significant correlation with relapse, we hypothesized that day-30 chimerism levels might predict relapse-free survival (RFS) and overall survival (OS). The 2-year estimated rates of RFS and OS were 33.9% (95% CI [25.1-42.9]) and 45.1% (95%CI [35.1-54.6]) respectively.
We conducted a landmark analysis to determine the associations between day-30 chimerism levels and RFS or OS (Table 4 ). Univariate analyses showed that both WB and T-cell chimerism strongly correlated with RFS (HR=0.90; p<0.001 for WB chimerism and HR=0.98; p=0.001 for T-cell chimerism), in addition to other factors (DRI, GvHD prophylaxis, CD8 dose and CD4/8 ratio). Multivariate models confirmed the predictive value of either WB chimerism or T-cell chimerism for RFS (Table 5) .
A similar approach revealed that WB and T-cell chimerism predicted OS in multivariate models that adjusted for the DRI, graft CD4/8 ratio and GvHD prophylaxis (HR=0.94; p=0.01 for WB chimerism, HR=0.99; p=0.05 for T-cell chimerism). Additional variables did not improve the OS model.
Graft-versus-host disease
The day-180 cumulative incidence rate of acute grade II-IV GvHD was 40.1% (95% CI [31.9-48.7]), and the 2-year incidence rate of moderate-severe chronic GvHD was 23.8% (95% CI [15.0-33.3]).
We conducted a landmark analysis to determine the associations between day-30 chimerism levels and grade II-IV acute GvHD. Patients (n=8) who had GvHD prior to day 30 were excluded. In univariate and multivariate analyses, day-30 WB and T-cell chimerism levels had no significant association with time to acute grade II-IV GvHD (Table S1 ). We also examined more immediate GvHD incidence rates (day-60 and day-100) and found no associations between chimerism levels on day-30 and the occurrence of acute GvHD at these time points (data not shown). A similar analysis for moderate-severe chronic GvHD (Table  S2 ) also showed no significant associations. Subset analyses of GvHD outcomes in patients who received different GvHD prophylaxis regimens also revealed no significant associations (data not shown).
Whole blood versus T-cell chimerism
All multivariate models were constructed with either WB or T-cell chimerism. Since these two variables were highly correlated (Figure 3 , r=0.61; p<0.0001), models that include both factors together arbitrarily choose one as significant and remove the other. To compare the predictive models that included WB and T-cell chimerism, we used the Akaike Information Criterion (AIC) that measures the relative goodness of fit of a statistical model and allows comparison between models, with the lower AIC reflecting a better model. We found that the AIC was lower (better) for T-cell chimerism compared to WB chimerism in prediction of all 3 outcomes -relapse (312 vs. 365), RFS (437 vs. 504) and OS (381 vs. 440), implying that day-30 T-cell chimerism may perform better in prediction of RIC HSCT outcomes.
DISCUSSION
In this study, we found that early donor-recipient chimerism levels, both in WB and in the T-cell subset, predicted subsequent relapse in HSCT recipients who received a peripheral blood stem-cell graft after a uniform RIC regimen. For each 1% difference in chimerism level, there was a difference of 10% (for WB chimerism) or 2% (for T-cell chimerism) in the relative risk for subsequent relapse. Based on our model, the projected risk for relapse at 1 year in patients who have WB chimerism levels of 90, 95 and 100% are 52, 34 and 21% respectively. Early chimerism levels also correlated with RFS and OS but not with acute or chronic GvHD. These associations did not differ between patients with myeloid and lymphoid diseases or acute leukemia versus other diseases. To the best of our knowledge, this study is the first to characterize early chimerism levels as a continuous variable that accurately predicts relapse and survival, and can be used to identify high-risk patients after RIC HSCT. These findings suggest that chimerism levels can be used to guide early posttransplant interventions in prospective clinical trials and possibly in standard clinical practice.
In our study, more than half of the relapsing patients experienced disease relapse by day 100. The outcome of relapsing patients was poor with a median survival of 4.9 months from the time of relapse and a 3-year survival of 18%. Similar outcomes have been previously reported [8, 9, 31-33], highlighting the importance of identifying patients at high risk for relapse at a very early time point after transplant.
The associations of day-30 chimerism with relapse, RFS and OS were significant, continuous and clinically meaningful. In assessing the relative goodness of fit of the models, we found an advantage to T-cell chimerism in prediction of all outcomes. These findings strengthen the rationale for the use of both WB and T-cell chimerism early after RIC HSCT.
The predictive value of peripheral blood chimerism testing after RIC HSCT has been previously examined. It was commonly, but not universally, observed that low T-cell chimerism predicts graft rejection whereas high T-cell chimerism is associated with GvHD [20-22, 34-36]. For relapse and survival outcomes, previous studies have demonstrated conflicting results. Early studies of RIC HSCT noted that complete T-cell donor chimerism seemed to precede malignant disease responses [21, 37] . These findings were not confirmed by other studies possibly due to heterogeneity in conditioning regimens and inclusion of Tcell depleting antibodies in some studies [19, 20, 38, 39] . Several studies attempted to use CD34 cell-specific chimerism and found that either a low level or a decline in the CD34-cell chimerism level predicted relapse, however this test is not always feasible early after transplant and is likely limited to patients with acute leukemia and myelodysplastic syndromes [14, 40] .
These conflicting results regarding the predictive value of chimerism testing possibly reflect the heterogeneity in studied populations in previous studies, inclusion of multiple conditioning regimens and graft sources, and inconsistent timing of testing. In our study, we aimed to overcome some of these barriers by studying patients who received a uniform, widely used conditioning regimen, and received peripheral blood stem cells only. We also focused on a single early time point (day 30), which we feel is the most relevant one after RIC HSCT due to the high incidence of early relapse. Another major difference is that most previous studies focused on achievement of complete donor chimerism using a historical threshold of 95% (or similar) whereas we handled chimerism levels as continuous variables. The rationale for our approach is that the analytic sensitivity of this assay has improved due to advances in technology and standardization. The EuroChimerism Consortium reported a detection limit of 0.8-1.6% and confidence intervals of 1.6-1.8% for donor chimerism levels >94% [41] . Our lab's internal validation is in line with these results, which allows us to take advantage of this molecular test with high precision. Our results show that the predictive value of both WB and T-cell chimerism levels is sustained across a wide range of values and not just at the historical threshold of 95%.
The findings of this study can be immediately applied. The primary advantage of chimerism measurement is that it can be done in all patients even in the absence of disease-specific information. This stands in contrast to other types of minimal residual disease (MRD) testing such as mutiparameter flow cytometry or quantitative PCR, which are limited to patients with a known immunophenotype or molecular abnormality [42] . These novel MRD assays are emerging as useful prognostic markers prior to transplant [43, 44] , but their clinical utility in post-transplant monitoring has been questioned, because the detection of leukemic cells early after transplant is not always predictive of relapse [45] . After RIC in particular, positive MRD is common and residual malignant cells can still be eradicated by the potent graft-versus-tumor response. A strategy that combines chimerism testing with other MRD methods can be envisioned to further increase the sensitivity of MRD detection and ensure that all patients benefit from early prognostication regardless of disease.
We did not identify any correlation between day-30 chimerism and GvHD. Previous studies have shown conflicting results on this association [19, 20, 22, 37] . In our cohort, acute GvHD was often delayed, with a median time to onset of 4.7 months post-transplant, which could explain why early chimerism measurement on day 30 failed to predict this outcome. It is possible that chimerism measurements at later time points, or trends between serial measurements, have a better predictive value for this outcome.
In our study, the early (day-30) achievement of high chimerism levels was strongly associated with a lymphopenic state prior to transplant. Lymphopenic individuals may have better homeostatic expansion of donor T-cells [46] and retrospective studies have noted that a higher number of anti-tumor therapies prior to transplant predicted early complete donor chimerism, which can be mechanistically linked to lymphopenia [19, 20, 22] . This was also shown prospectively in a study in which accelerated donor engraftment was achieved with lymphodepleting chemotherapy prior to RIC HSCT for lymphoma [47] . Our results demonstrate that lower pre-transplant lymphocyte counts are associated with faster engraftment in any disease, not just in lymphomas, suggesting that aggressive lymphodepletion prior to transplant can be used broadly to accelerate donor cell engraftment. Ultimately, randomized studies will be required to demonstrate the effect of lymphodepletion on transplant outcomes.
Certain limitations to our study should be noted. For uniformity, we focused on a single RIC regimen (Flu/Bu2), which is the most commonly used RIC regimen according to 2011 CIBMTR data. Whether the kinetics of engraftment differs among RIC regimens is unknown, but it has been suggested that melphalan-based regimens achieve complete T-cell chimerism more rapidly, implying that the predictive value of chimerism should be validated for other regimens [19] . Our study also analyzed the outcomes of a heterogeneous patient population in terms of disease characteristics (e.g., disease type, cytogenetic risk). The DRI that was recently validated in more than 13,000 patients was used to adjust our analyses to overcome this barrier. In addition, we analyzed broad disease categories (myeloid vs. lymphoid, acute leukemia vs. others) and found no significant impact on any of the outcomes or interactions with any of the important covariates. However, the small number of patients in some of the disease categories precluded meaningful disease-specific analyses.
The clinical utility of any prognostic biomarker is limited if not tied with a strategy that prevents overt relapse. It is known that reduction of immunosuppression and DLI can convert mixed chimerism to complete donor chimerism and even eliminate measurable residual disease [45, [48] [49] [50] . Whether this can be safely, rapidly, and meaningfully achieved without excessive toxicity as early as 30 days after HSCT is unknown. More recently, maintenance regimens such as methyltransferase inhibitors and targeted therapies (e.g., Flt3 inhibitors) have entered clinical trials in the early post-transplant setting [51-54], but similarly, whether these interventions can be safely initiated very early after transplant remains to be determined. The findings of our study suggest that low WB or T-cell chimerism levels on day 30 after RIC HSCT indicate a higher risk for relapse independent of any other indicators. This may help inform patient selection for approaches such as enhanced tapering or withdrawal of immunosuppression, pre-emptive DLI or experimental therapy. The safety and efficacy of these approaches will need to be examined in prospective clinical trials.
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